Haiying Zhan, MD, PhD
Assistant Professor of PathologyDownloadHi-Res Photo
Cards
Appointments
Pathology
Primary
Contact Info
About
Titles
Assistant Professor of Pathology
Appointments
Pathology
Assistant ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellowship
- Yale School of Medicine (2021)
- Fellowship
- Roswell Park Comprehensive Cancer Center (2020)
- Residency
- State University of New York at Buffalo (2019)
- PhD
- University of Connecticut Health Center (2012)
- MD
- Tongji Medical University (1998)
Board Certifications
Anatomic & Clinical Pathology
- Certification Organization
- AB of Pathology
- Original Certification Date
- 2019
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Haiying Zhan's published research.
Publications Timeline
A big-picture view of Haiying Zhan's research output by year.
Malini Harigopal, MD
Uma Krishnamurti, MD, MBBS, PhD
Neal Fischbach, MD
Tong Sun, MD, PhD
6Publications
4Citations
Publications
2023
Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature
Mogica J, Tang H, Liang Y, Zhong M, Hui P, Harigopal M, Krishnamurti U, Fischbach N, Zhan H. Prognostic impact of reduced HER2 protein expression in post-neoadjuvant therapy resection specimens: A single institution experience and review of the literature. The Breast 2023, 72: 103586. PMID: 37812963, PMCID: PMC10568274, DOI: 10.1016/j.breast.2023.103586.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsHER2 IHC 3Human epidermal growth factor receptor 2Kaplan-Meier survival analysisHER2-IHC expressionPathologic complete responseResidual diseaseIHC 3Breast cancerIHC expressionSurvival analysisSuperior disease-free survivalEpidermal growth factor receptor 2Intensive adjuvant therapyPost-therapy surveillanceYale Cancer CenterDisease-free survivalGrowth factor receptor 2Recurrence-free survivalSingle institution experienceLow recurrence rateFactor receptor 2HER2 protein expressionAdjuvant trialsNeoadjuvant treatmentAdjuvant therapyThe correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas
Moreira-Dinzey J, Zhan H, Rozenblit M, Krishnamurti U, Harigopal M, Zhong M, Liang Y. The correlation of ESR1 genetic aberrations with estrogen receptor and progesterone receptor status in metastatic and primary estrogen receptor-positive breast carcinomas. Human Pathology 2023, 137: 56-62. PMID: 37127079, DOI: 10.1016/j.humpath.2023.04.017.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic tumorsBreast carcinomaGenetic aberrationsPR statusPrimary tumorBreast cancerControl groupER/PR statusEstrogen receptor-positive breast carcinomasER-positive breast cancerER positivity rateMetastatic breast cancerProgesterone receptor statusMetastatic breast carcinomaMore liver metastasesPrimary breast carcinomaWild-type groupEstrogen receptor 1 geneReceptor 1 geneWild-type controlsLiver metastasesReceptor statusClinicopathological featuresER expressionControl tumors
2022
Further Characterization of Clinicopathologic Features of Cystic Neutrophilic Granulomatous Mastitis
Liang Y, Zhan H, Krishnamurti U, Harigopal M, Sun T. Further Characterization of Clinicopathologic Features of Cystic Neutrophilic Granulomatous Mastitis. American Journal Of Clinical Pathology 2022, 158: 488-493. PMID: 35899981, DOI: 10.1093/ajcp/aqac074.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCystic neutrophilic granulomatous mastitisGranulomatous mastitisClinicopathologic characteristicsClinicopathologic featuresHigher Breast Imaging ReportingUnique infectious diseaseHospital-based cohortDistinct clinicopathologic featuresMass-like lesionCase-control studyData System scoreBreast Imaging ReportingPainful lesionsRadiologic studiesClinicopathologic profileSystem scoreImaging ReportingDemographic featuresInfectious diseasesPatientsLesionsDiseaseMastitisFurther characterizationSmokersTouching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS.
Khoury T, Quinn M, Tian W, Yan L, Zhan H. Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS. Histopathology 2022, 80: 291-303. PMID: 34379814, DOI: 10.1111/his.14539.Peer-Reviewed Original Research
2021
Significance of Removing Comedonecrosis as an Exclusion Criterion in Mammary Low-Risk Ductal Carcinoma In Situ Managed in an Active Surveillance Clinical Trial.
Zhan H, Quinn M, Tian W, Yan L, Khoury T. Significance of Removing Comedonecrosis as an Exclusion Criterion in Mammary Low-Risk Ductal Carcinoma In Situ Managed in an Active Surveillance Clinical Trial. Am J Clin Pathol 2021, 156: 596-606. PMID: 33769445, DOI: 10.1093/ajcp/aqaa276.Peer-Reviewed Original Research
2020
Molecular basis of junctional current rectification at an electrical synapse.
Shui Y, Liu P, Zhan H, Chen B, Wang ZW. Molecular basis of junctional current rectification at an electrical synapse. Sci Adv 2020, 6: eabb3076. PMID: 32923588, DOI: 10.1126/sciadv.abb3076.Peer-Reviewed Original Research